Edition:
Deutschland

Aradigm Corp (ARDM.OQ)

ARDM.OQ on NASDAQ Stock Exchange Capital Market

1.30USD
15 Aug 2018
Change (% chg)

$-0.06 (-4.41%)
Prev Close
$1.36
Open
$1.35
Day's High
$1.35
Day's Low
$1.30
Volume
3,957
Avg. Vol
10,753
52-wk High
$7.26
52-wk Low
$1.04

ARDM.OQ

Chart for ARDM.OQ

About

Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company's lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery... (more)

Buy/Sell

Sell Hold Buy
3.00 Mean rating from 1 analysts

Overall

Beta: 1.63
Market Cap(Mil.): $55.61
Shares Outstanding(Mil.): 15.11
Dividend: --
Yield (%): --

BRIEF-Aradigm Reports Q4 Loss Per Share Of $0.28

* ARADIGM ANNOUNCES FOURTH QUARTER 2017 AND FULL YEAR FINANCIAL RESULTS

BRIEF-Aradigm Submits Marketing Authorisation Application To EMA For EU Marketing Approval Of Linhaliq

* ARADIGM SUBMITS MARKETING AUTHORISATION APPLICATION (MAA) TO EMA FOR EU MARKETING APPROVAL OF LINHALIQ IN NON-CYSTIC FIBROSIS BRONCHIECTASIS Source text for Eikon: Further company coverage:

BRIEF-Aradigm Says Received Nasdaq Notice It Is No Longer In Compliance With Requirements

* ARADIGM- RECEIVED NASDAQ NOTICE THAT AS OF JOHN SIEBERT APPOINTMENT,NO LONGER IN COMPLIANCE WITH NASDAQ'S INDEPENDENT DIRECTOR,AUDIT COMMITTEE REQUIREMENTS

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie -2.06%
Rohstoffe -0.68%
Industrie -1.05%
Konjunktur abhängige Waren & Dienstleistungen -0.09%
Konjunktur unabhängige Waren & Dienstleistungen -0.51%
Finanzindustrie -0.32%
Pharma -1.11%
Technologie -0.05%
Telekommunikation +0.37%